|
|
WHAT'S NEW
IBDoc® Talk - Tips & Tricks Teleconference
New Updates for IBDoc® Validated Smartphones List
IBDoc® provides sophisticated technology which enables IBD patients to perform quantitative calprotectin testing themselves, in just three easy steps, reading results using their smartphones. Recent updates to the IBDoc® Validated Smartphones List, now reveals over 36 supported Android and iOS Devices!
New Health Canada Licence
BÜHLMANN is proud to announce a new Health Canada licence for the Quantum Blue® Adalimumab. This assay is unique in the market, being the first test to provide fast, reliable information for adalimumab and correlates well with the standard routine ELISAs for adalimumab level determinations.
New Quantum Blue® fCAL Tutorial
Check out the latest tutorial for Quantum Blue® fCAL. View this demonstration of CALEX® Cap extraction and quantitative fecal calprotectin measurement using the Quantum Blue® fCAL rapid test technology.
CITATIONS
BÜHLMANN MRP8/14 ELISA Citations
Check out the new addition to our citation menu on our website for the BÜHLMANN MRP8/14 ELISA.
BÜHLMANN HIGHLIGHTS
The ACE kinetic kit from BÜHLMANN provides ready to use Substrate and highly stable Calibrator and Controls, offering a maximum convenience and accuracy. Reconstituted Calibrator and Controls provided with the kits are stable for 6 months at 2-8°C. The substrate has an onboard-stability up to 3 months. Different package sizes are available (2×50, 100 and 1200 tests). Application notes are available for most common clinical chemistry analyzers.
ACE Kinetic is FDA 510(k) cleared. For in vitro Diagnostic Use.
Health Canada License: HC80727
PROMOTION
An FDA-Cleared Gastrointestinal Test to Distinguish IBD from IBS
Calprotectin is a highly-sensitive clinical biomarker shown to be extremely useful as an aid in diagnosis of inflammatory diseases in the gastrointestinal tract.
The BÜHLMANN fCAL® ELISA is an in vitro diagnostic assay intended for the quantitative measurement of fecal calprotectin in human stool. The BÜHLMANN fCAL® ELISA aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohns disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.
This FDA 510k cleared, non-invasive, sensitive and specific assay is accurate, precise, efficient and offers reliable information to aid clinicians in selecting patients for further diagnostic procedures.
BUHLMANN DIAGNOSTICS CORP
BÜHLMANN is unique, independent, and reliable in every aspect of its business from the outstanding quality of its products, its excellent after-sales services, and its remarkable scientific innovations. The establishment of BDC is a statement of the importance of you, our customers and our commitment to understanding your needs. Our North American affiliate will help us to continue to foster closer relationships with our customers and enhance our customer support interactions as well as meet your requirements for future BÜHLMANN products. Quality is not just a statement, but part of our daily mission.
105 Route 101A, Suite 1,
Amherst, NH 03031 USA
Ph: (844) 300-9799
[email protected]
www.buhlmannlabs.com
|
|
|
|